After completing his PhD in microbiology and immunology at the University of New South Wales, Leighton Clancy joined the Cellular Therapies research group and the Westmead Hospital Blood and Marrow Transplant (BMT) Laboratory in 2006. His primary interest has been to expand the activities of the BMT laboratory to address complications that arise following transplantation through early phase clinical trials that aim to treat infections and prevent relapse of cancer. He is currently co-scientific director of the BMT laboratory and supervises the manufacture of T cell therapies for local investigator initiated clinical trials.

Immunology, Cellular Therapy, Transplantation, Clinical Trials


Cancer, Infection and Immunological Conditions

Research Focus

Leighton's research interest is in T cell based therapies for the treatment of infections and malignancy in stem cell transplant recipients. In particular his research focus has been on the transition of pre-clinical research to clinically acceptable manufacturing protocols and the Cellular Therapies group clinical trials program.

Other Affiliations

Sydney Cellular Therapies Laboratory, NSW Health Pathology